Braskem SA (BAK) Earnings Date & Reports

Key Takeaways

• Analysts expect Braskem S.A. (BAK) to report 1Q26 EPS around -$0.39 to -$0.43, reflecting ongoing challenges in the petrochemical sector.
• Consensus revenue estimates hover near $3.67 billion for the quarter ending March 2026, with limited analyst coverage.
• Recurring EBITDA is a key focus, following Q4 2025's $109 million amid weak spreads and volumes.
• Investors will watch Brazil segment performance, utilization rates, and updates on naphtha optimization initiatives.
• Next earnings release scheduled for May 12, 2026, per company IR calendar.
• Stock trades around $3.31, sensitive to global petrochemical cycles and currency fluctuations.

Earnings Context and Why It Matters

Braskem S.A. (BAK), the largest resin producer in the Americas, operates in a volatile petrochemical market marked by oversupply, weak spreads, and geopolitical tensions. The upcoming 1Q26 earnings, covering January to March 2026, come after a tough 2025, where full-year recurring EBITDA fell 49% to $557 million, driven by lower volumes in Brazil and negative results in the US/Europe. Investors are focused on signs of recovery in spreads, utilization rates (59% ethylene in Brazil Q4 2025), and progress on strategic shifts like reducing naphtha dependency to 60% by 2030. With adjusted net debt at $7.5 billion and corporate leverage at 14.74x, liquidity preservation remains critical amid Brazil's real appreciation and global demand softness. This report could signal if transformation efforts are gaining traction in a downcycle.

Earnings Expectations

Consensus estimates for 1Q26 point to EPS of approximately -$0.39 (StockInvest.us) to -$0.43 (Public.com), continuing losses from Q4 2025's -$1.01 actual vs. -$1.00 expected. Revenue is forecasted around 19 billion BRL (~$3.67 billion USD), aligning with Yahoo Finance's current quarter estimate of 19.01B BRL, though analyst coverage is thin (1-2 firms). Key metrics include recurring EBITDA, expected to improve from Q4's $109 million if spreads recover as per external consultancies' 50% uptick outlook into 1Q26. Watch Brazil/South America (prior $698M FY EBITDA), utilization rates, resin spreads (Q4: $308/ton), and Mexico's stability post-maintenance. Historically, Braskem beats/misses vary; Q4 missed slightly on EPS/revenue. No formal guidance issued, but management highlights liquidity measures and renewables push. Stock reactions average 5-10% post-earnings on spread surprises.

AI Screener

Tickeron’s AI Screener is an AI-powered stock and ETF discovery tool that helps traders and investors filter the market based on technical patterns, fundamentals, trends, volatility, and AI-driven signals. Users can scan thousands of stocks and ETFs using customizable filters such as industry, market capitalization, technical indicators, price patterns, and performance metrics. The screener identifies trade ideas, trending stocks, breakout candidates, and market opportunities more efficiently than manual screening, empowering data-driven decisions in dynamic markets like petrochemicals. Explore it today to spot potential plays ahead of earnings.

Market Reaction and Investor Sentiment

Heading into 1Q26 earnings, sentiment is cautious, with BAK shares at $3.31 after Q4's 10% after-hours drop on missed results and $10.3B net loss reveal. Implied volatility suggests 8-12% move expected. Risks include persistent weak spreads, real strength hurting exports, and Alagoas provisions (BRL3.5B remaining). Positives: antidumping duties on PE imports, REIQ tax benefits, and potential spread recovery. Analysts rate Reduce/Hold, target ~$3.87. Options flow shows puts dominant, reflecting downcycle fears.

Forward Outlook and Key Factors to Monitor

Post-1Q26, focus shifts to execution of Braskem's Transformation Program, targeting naphtha optimization, gas-based expansion, and renewables migration to 1M tons/year by 2030. Naphtha reliance drops to 60/40 gas/ethanol mix, potentially boosting margins amid volatile oil.

Key monitors: petrochemical spreads (Q4 spreads down 13-15% QoQ), Brazil utilization (target 68% FY avg.), Mexico ops post-TQPM terminal (92% Q4 utilization). Capex ~US$465M in 2026 (ex-Idesa/REIQ), prioritizing reliability and sustainability like bioMEG/bioMPG JVs.

Liquidity key with $2.1B cash (incl. $1B standby to Dec 2026), leverage 14.74x, debt avg. 4.9 years. Tax incentives (PRESIQ, REIQ to 5.8%) and antidumping (PE from US/Canada, 20% import tax on PVC/PE/PP) could aid competitiveness. Alagoas resolution and Braskem Idesa debt profile remain watches. No price targets; balanced view on cycle recovery vs. oversupply.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer. Disclaimers and Limitations